$KTTA

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW)

-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation has achieved stable disease and ...

Original reporting
Benzinga · Globe Newswire
Published Nov 20, 2025, 9:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 20, 2025, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - Pasithea Therapeutics (NASDAQ:KTTA), Pasithea Therapeutics (NASDAQ:KTTAW) — source image
Decision brief

The 30-second read

$KTTABullishHigh
01

Why it matters

The trial results may accelerate the company's development timeline and attract investor interest, potentially elevating stock price.

02

Market read

The news is highly relevant for biotech investors and analysts tracking oncology developments.

03

What to watch

Regulatory hurdles or delays in subsequent trial phases could negate initial optimism.

Timing: Immediate, as the news is recent and impactful

Background

Pasithea Therapeutics is developing PAS-004, a therapy targeting advanced cancers, with recent positive Phase 1 data indicating clinical activity.

Company-level read

Ticker impact

$KTTABullishHigh confidence
Context

The news pertains directly to Pasithea Therapeutics, listed under ticker KTTA, with positive clinical trial data indicating potential stock appreciation.

Expected impact

Moderate to significant short-term increase in stock price, contingent on further clinical validation.

Evidence & confidence

The announcement of positive trial data, including partial responses and a favorable safety profile, typically boosts investor confidence and stock valuation, especially for biotech firms with promising therapies.

Market effects

Potential positive impact on biotech and oncology sectors

Likely to influence U.S. biotech indices

Limited, as the news pertains to a specific company's clinical trial data

Counterpoint

The positive data may already be priced in; upcoming trial phases could reveal setbacks, leading to volatility.

Key entities

  • Pasithea Therapeutics

    Biotech firm focusing on innovative cancer therapies.

  • PAS-004

    Therapeutic agent demonstrating clinical activity in Phase 1 trials.

Related articles

$KTTAMedAI 9/10

Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.